Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Bonfiglio F, Bruscaggin A, Guidetti F, di Bergamo LT, Faderl M, Spina V, et al. Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood. 2022;139(5):732-747.

Buyukozkan M, Alvarez-Mulett S, Racanelli AC, Schmidt F, Batra R, Hoffman KL, et al. Integrative metabolomic and proteomic signatures define clinical outcomes in severe COVID-19. iScience. 2022;25(7):104612.

Boyraz B, Hung YP. Spindle cell tumors of the pleura and the peritoneum: pathologic diagnosis and updates. APMIS. 2022;130(3):140-154.

Ding R, Prasanna P, Corredor G, Barrera C, Zens P, Lu C, et al. Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome. NPJ Precis Oncol. 2022;6(1):33.

Haas M, Mirocha J, Amann K, Bajema IM, Barisoni L, Becker JU, et al. Impact of Consensus Definitions on Identification of Glomerular Lesions by Light and Electron Microscopy. Kidney Int Rep. 2022;7(1):78-86.

Kwon O-, Zhang B, Jia D, Zhang L, Wei X, Zhou Z, et al. Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022;41(9):1309-1323.

Lally L, Narula N, Goodfellow N, Luqmani R, Pisapia D, Spiera RF. Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy. J Rheumatol. 2022;49(8):908-912.

Brendel M, Getseva V, Assaad MA, Sigouros M, Sigaras A, Kane T, et al. Weakly-supervised tumor purity prediction from frozen H&E stained slides. EBioMedicine. 2022;80:104067.

Choi SY, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules. 2022;12(11).

Berchuck JE, Boiarsky D, Silver R, Sunkara R, McClure HM, Tsai HK, et al. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. JCO Precis Oncol. 2022;6:e2200329.